COVID-19 for people affected by Duchenne or Becker
WHAT WE KNOW ABOUT COVID-19 What do we know about COVID-19 for people affected by Duchenne or Becker? Due to the increasing concerns regarding the COVID-19 virus for people with Duchenne and [...]
Viltolarsen under priority review by the FDA
The U.S. Food & Drug Administration (FDA) had accepted the filing of a New Drug Application (NDA) under the priority review for viltolarsen in patients with Duchenne Muscular Dystrophy (DMD) [...]
Translarna™ Preserves the ability to walk for longer in children with DMD
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarna™ (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy [...]
What’s next for edasalonexent in 2020?
La Force is happy to share the latest edition of the Catabasis Connection newsletter about the Phase 3 PolarisDMD trial enrolled in the expected patient population and their partnership with [...]
Sarepta Therapeutics Announces Partnership with Roche
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 [...]
FDA grants accelerated approval to Vyondys 53
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 Source: Sarepta [...]
A DMD gene therapy has been placed on clinical hold
Following the occurrence of a safety incident, the FDA has placed on hold the clinical trial for SGT-001, the Solid’s gene therapy candidate for Duchenne muscular dystrophy (DMD). This [...]
Positive data with vamorolone in DMD
Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne Muscular Dystrophy La Force is happy to share this press release provided by Santhera [...]
Translarna™ (ataluren) Slows Disease Progression in Patients with DMD
PTC Therapeutics announces new real-world analysis demonstrating Translarna™ (ataluren) slows disease progression in patients with Duchenne muscular dystrophy La Force is happy to share [...]
PolarisDMD Trial in DMD has exceeded target enrollment
Phase 3, PolarisDMD trial of edasalonexent in DMD has exceeded target enrollment La Force is happy to share the latest edition of the Catabasis Connection newsletter Catabasis [...]
